mRNA Coronavirus Disease 2019 Vaccine-Associated Myopericarditis in Adolescents: A Survey Study

J Pediatr. 2022 Apr;243:208-213.e3. doi: 10.1016/j.jpeds.2021.12.025. Epub 2021 Dec 22.

Abstract

In this survey study of institutions across the US, marked variability in evaluation, treatment, and follow-up of adolescents 12 through 18 years of age with mRNA coronavirus disease 2019 (COVID-19) vaccine-associated myopericarditis was noted. Only one adolescent with life-threatening complications was reported, with no deaths at any of the participating institutions.

Keywords: mRNA COVID-19 vaccine-associated myopericarditis; outcomes; survey; variability.

Publication types

  • Case Reports
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • COVID-19 Vaccines / adverse effects
  • COVID-19* / prevention & control
  • Humans
  • Myocarditis* / epidemiology
  • Myocarditis* / etiology
  • RNA, Messenger

Substances

  • COVID-19 Vaccines
  • RNA, Messenger